Key features and details | |
Cat. No. | MABL-761 |
Name | Anti-CD19 mAbs |
Clone No. | AFD- CAT-13.1E10 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | therapeutics |
Species Reactivity | Human |
Basic Information | |
Specificity | CAT 13.1E10 antibody recognises CD19, which is a transmembrane glycoprotein that regulates B lymphocyte development, activation, and differentiation. |
Alternative Name | Leu12; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19 T-cell surface antigen Leu-12; CD19; B4; CAT 13.1E10 |
UniProt | P15391 |
Immunogen | This antibody was raised by immunising mice against CD19. |
Application Notes | This antibody is recommended for targeting and analysis of B cells. CAT-13.1E10 was used as a part of a fusion molecule aimed at intracellular delivery of BINDI in order to establish a potential treatment method of EBV-positive B lymphoma in a xenograft mouse model (US20160376333A1). |
Antibody First Published | Procko et al. University of Washington, 2017. Polypeptides to inhibit epstein barr viral protein BHRF1 and B cell lymphoma family proteins. U.S. Patent 9,750,814. |
Note on publication | This patent describes the potential therapeurical use of CAT-13.1E10 antibody. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
